Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
11 studies found for:    Fresolimumab
Show Display Options
Rank Status Study
1 Completed Safety and Imaging Study of GC1008 in Glioma
Condition: Primary Brain Tumors
Interventions: Other: 89Zr-GC1008;   Drug: GC1008
2 Active, not recruiting Fresolimumab and Radiotherapy in Metastatic Breast Cancer
Condition: Metastatic Breast Cancer
Interventions: Drug: Fresolimumab;   Radiation: Radiation Therapy
3 Completed Fresolimumab In Systemic Sclerosis
Condition: Diffuse Systemic Sclerosis
Intervention: Drug: Fresolimumab
4 Completed A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)
Condition: Primary Focal Segmental Glomerulosclerosis
Interventions: Drug: fresolimumab;   Drug: Placebo
5 Recruiting SABR-ATAC: A Trial of TGF-beta Inhibition and Stereotactic Ablative Radiotherapy for Early Stage Non-small Cell Lung Cancer
Conditions: Stage IA Non-Small Cell Lung Carcinoma;   Stage IB Non-Small Cell Lung Carcinoma
Interventions: Biological: Fresolimumab;   Other: Pharmacological Study;   Radiation: Stereotactic Body Radiation Therapy
6 Completed Safety Study of GC1008 in Patients With Focal Segmental Glomerulosclerosis (FSGS) of Single Doses of GC1008 in Patients With Treatment Resistant Idiopathic FSGS
Condition: Focal Segmental Glomerulosclerosis
Intervention: Biological: GC1008
7 Completed Safety and Efficacy Study of GC1008 to Treat Renal Cell Carcinoma or Malignant Melanoma
Conditions: Carcinoma, Renal Cell;   Melanoma
Interventions: Biological: GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody;   Biological: GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ ) Monoclonal Antibody
8 Completed Study of GC1008 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Condition: Idiopathic Pulmonary Fibrosis
Intervention: Biological: GC1008
9 Completed Part 2 of Phase 1 Study of GC1008 to Treat Advanced Melanoma (Part 2 Will Only Accept and Treat Patients With Advanced Malignant Melanoma)
Condition: Renal Cell Carcinoma
Intervention: Drug: Anti-Transforming Growth Factor-beta (GC 1008)
10 Completed Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma
Condition: Pleural Malignant Mesothelioma
Intervention: Drug: GC1008
11 Terminated
Has Results
Anti-TGF-beta Therapy in Patients With Myelofibrosis
Conditions: Myelofibrosis;   Primary Myelofibrosis;   Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase;   Post-essential Thrombocythemia Related Myelofibrosis
Intervention: Biological: monoclonal antibody to TGF-beta

Indicates status has not been verified in more than two years